{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:34:54Z","timestamp":1782538494810,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacoresistant seizures remain a major challenge for the global epilepsy community. Hence, approval of highly purified pharmaceutical grade cannabidiol (CBD) for Dravet syndrome (DS), Lennox\u2013Gastaut syndrome (LGS), and refractory seizures associated with tuberous sclerosis complex (TSC) generated significant interest, both in the medical community and public domain. However, there are limited data on the availability and accessibility of CBD and other cannabinoids for the treatment of drug\u2010resistant epilepsy worldwide. The International League Against Epilepsy (ILAE) Plant\u2010Based Therapy Task Force commissioned a working group in 2022 to conduct a survey through the chapters to understand the global availability of cannabinoids for the treatment of epilepsy, and to identify the possible factors affecting the accessibility and affordability of these products. The survey was conducted between June and December 2023. Responses were screened, tabulated, and analyzed using pre\u2010set criteria. Among the 126 ILAE Chapters, 86 (68%) completed the survey questionnaire. Thirty\u2010two countries had regulatory approval for cannabinoids for the treatment of epilepsy at the time of this survey, of which 21 (65.6%) reported approval only for CBD. Twenty\u2010three chapters (71.8%) in this group reported cannabinoids to be unaffordable, and 18 (56.2%) reported they were difficult to access. Cannabinoids were not approved formally for epilepsy in 54 countries (62.7%). Over\u2010the\u2010counter availability of unapproved products containing cannabinoids was reported from 34 countries (39.5%). Forty\u2010seven chapters (54.6%) indicated the existence of traditional plant\u2010based products for epilepsy in their respective countries, of which 16 had products containing cannabinoids. Forty\u2010two chapters (48.8%) expressed a need for targeted advocacy efforts from the ILAE to improve the accessibility of cannabinoids for the management of epilepsy. This survey should act as a premise for developing better concerted strategies to improve the availability and affordability of cannabinoids for the management of epilepsy across the world.<\/jats:p>","DOI":"10.1111\/epi.18622","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T15:20:05Z","timestamp":1758640805000},"page":"4639-4653","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Availability and affordability of cannabinoids for epilepsy treatment across different geographic settings\u2014A survey from the\n                    <scp>ILAE<\/scp>\n                    Plant\u2010Based Therapy Task Force"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-3619","authenticated-orcid":false,"given":"Kollencheri Puthenveettil","family":"Vinayan","sequence":"first","affiliation":[{"name":"Department of Pediatric Neurology and Advanced Center for Epilepsy Amrita Institute of Medical Sciences  Cochin Kerala India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-7601","authenticated-orcid":false,"given":"Ali Akbar","family":"Asadi\u2010Pooya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Epilepsy Research Center Shiraz University of Medical Sciences  Shiraz Iran"},{"name":"Jefferson Comprehensive Epilepsy Center Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-2086","authenticated-orcid":false,"given":"Aruna Setumadhava","family":"Jyotsna","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology Apollo BGS Hospital  Mysore Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya N.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology and Advanced Center for Epilepsy Amrita Institute of Medical Sciences  Cochin Kerala India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-3483","authenticated-orcid":false,"given":"Siegward\u2010M.","family":"Elsas","sequence":"additional","affiliation":[{"name":"Department of Neurology Klinik Arlesheim  Arlesheim Switzerland"},{"name":"Department of Research Klinik Arlesheim  Arlesheim Switzerland"},{"name":"Department of Neurology University Hospital of Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital of Basel  Basel Switzerland"},{"name":"Gerhard Kienle Chair for Theory of Medicine, Integrative and Anthroposophic Medicine Witten\/Herdecke University  Witten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-8912","authenticated-orcid":false,"given":"Cecilie","family":"Johannessen Landmark","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Oslo Metropolitan University, The National Centre for Epilepsy, Member of the ERN EpiCare  Oslo Norway"},{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2921-8882","authenticated-orcid":false,"given":"Motlalepula","family":"Matsabisa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, African Medicines Innovations and Technologies Development (AMITD), School of Clinical Medicines, Faculty of Health Sciences University of the Free State  Bloemfontein South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-7365","authenticated-orcid":false,"given":"Boulenouar","family":"Mesraoua","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporate and Weill Cornell Medical College  Department of Neurology and Comprehensive Epilepsy Program Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-6029","authenticated-orcid":false,"given":"Finbar","family":"O'Callaghan","sequence":"additional","affiliation":[{"name":"Clinical Neuroscience Section UCL Great Ormond Street Institute of Child Health  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-4713","authenticated-orcid":false,"given":"Elizabeth","family":"Thiele","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-9415","authenticated-orcid":false,"given":"Chunbo","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Jiangxi Medical College Nanchang University  Nanchang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-3555","authenticated-orcid":false,"given":"Kate","family":"Riney","sequence":"additional","affiliation":[{"name":"Neurosciences Unit Queensland Children's Hospital  South Brisbane Queensland Australia"},{"name":"Faculty of Medicine University of Queensland  South Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14929"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16849"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1141"},{"key":"e_1_2_13_5_1","unstructured":"U.S. Food & Drug Administration (FDA).Epidiolex\u00ae (cannabidiol) oral solution: highlights of prescribing information. Available from:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=210365. Accessed 24 Mar 2025."},{"key":"e_1_2_13_6_1","unstructured":"European Medicines Agency.Epidyolex\u00ae 100 mg\/ml oral solution: summary of product characteristics.2022. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/epidyolex\u2010epar\u2010product\u2010information_en.pdf. Accessed 24 Mar 2025."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12699"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18136719"},{"key":"e_1_2_13_9_1","unstructured":"lnternational League Against Epilepsy.2024. Available from:https:\/\/www.ilae.org\/about\u2010ilae\/regions. Accessed 7 Aug 2024"},{"key":"e_1_2_13_10_1","unstructured":"World Bank Country and Lending Groups. Available from:https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519\u2010world\u2010bank\u2010country\u2010and\u2010lending\u2010groups. Accessed 7 Aug 2024"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17155"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.4102\/phcfm.v11i1.2136"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-032816-045128"},{"key":"e_1_2_13_14_1","first-page":"1574","article-title":"Who proposes rescheduling cannabis to allow medical applications","volume":"364","author":"Susan M","year":"2019","journal-title":"BMJ"},{"key":"e_1_2_13_15_1","unstructured":"The International Drug Control Conventions Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol as at 22 January 2021. Available from:https:\/\/docs.un.org\/en\/st\/CND\/1\/ADD.1\/REV.7. Accessed 15 Jun 2025."},{"key":"e_1_2_13_16_1","unstructured":"International cannabis policy study. Available from:https:\/\/cannabisproject.ca. Accessed 7 Jul 2025."},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v13i1.4430"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216556"},{"issue":"8","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022101","article-title":"Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross\u2010sectional survey","volume":"3","author":"Karanges EA","year":"2018","journal-title":"BMJ Open"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00377-0"},{"key":"e_1_2_13_21_1","unstructured":"Therapeutic Goods Administration Department of Health and Aged Care Australian Government.Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods. Last updated: 1 Oct 2024. Available from:https:\/\/www.tga.gov.au\/sites\/default\/files\/special\u2010access\u2010scheme\u2010guidance\u2010forhealth\u2010practitioners\u2010and\u2010sponsors.pdf. Accessed 6 Nov 2024"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102935"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6613"},{"key":"e_1_2_13_24_1","unstructured":"FDA.FDA and Cannabis: Research and Drug approval process. Available from:https:\/\/www.fda.gov\/news\u2010events\/public\u2010health\u2010focus\/fda\u2010and\u2010cannabis\u2010research\u2010and\u2010drug\u2010approval\u2010process. Accessed 6 Jul 2025"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01313"},{"key":"e_1_2_13_26_1","unstructured":"The Central Drugs Standard Control Organisation (CDSCO).List of new drugs approved in the year 2023 till date. Available from:https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadApprovalNewDrugs\/new%20drugs%20approval%202023%20oct.pdf. Accessed 7 Aug 2024"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.571832"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108496"},{"key":"e_1_2_13_29_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.Medical use of cannabis and cannabinoids: Questions and answers for policymaking.2018. Available from:https:\/\/www.drugsandalcohol.ie\/30034\/. Accessed 7 Aug 2024."},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14242"},{"key":"e_1_2_13_31_1","unstructured":"Therapeutic goods administration Department of Health and Aged Care Australian Government.Medicinal cannabis\u2014guidance documents. Last updated: 28 Nov 2024. Available from:https:\/\/www.tga.gov.au\/node\/732373. Accessed 5 Dec 2024"},{"key":"e_1_2_13_32_1","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academics of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An evidence Review and Research Agenda","year":"2017"},{"key":"e_1_2_13_33_1","unstructured":"British Paediatric Neurology Association.Guidance on the use of cannabis\u2010based products for medicinal use in children and young people with epilepsy. Last updated: 31 Oct 2018. Available from:https:\/\/bpna.org.uk\/userfiles\/BPNA_CBPM_Guidance_Oct2018.pdf. Accessed 7 Aug 2024."}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.18622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.18622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.18622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:01:44Z","timestamp":1779109304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.18622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/epi.18622"],"URL":"https:\/\/doi.org\/10.1111\/epi.18622","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"2025-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}